BioNTech SE - ADR vs Costco Wholesale Corporation — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Costco Wholesale Corporation trades at $921.56 (market cap $408.78B). The key difference: Costco Wholesale Corporation is far larger — about 17.9× BioNTech SE - ADR's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | COST | |
|---|---|---|
Market Cap | $22.86B | $408.78B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $1.09K |
52-Week Low | $83.89 | $849.63 |
Enterprise Value | $6.53B | $396.92B |
Dividend Yield | — | 0.64% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Costco (COST) trades at $926.43, up 1.11% with strong fundamentals including 11.3% March sales growth and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but maintains solid profitability with $8.1B net income and expanding margins. Recent membership fee increases and warehouse expansion support long-term growth, though high valuation multiples present near-term pressure.
Outlook remains positive with analyst consensus at $1,120 price target (65% buy ratings), but investors should monitor valuation sustainability amid technical weakness. Key risks include competitive pressures and economic sensitivity, while institutional accumulation and strong cash flow generation provide fundamental support.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →